ATH-1020 is under clinical development by Athira Pharma and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ATH-1020’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATH-1020 is under development for the treatment of neuropsychiatric indications including anxiety disorders, depression and schizophrenia. It is administered by the oral route formulated as a capsule. It acts by targeting hepatocyte growth factor and hepatocyte growth factor receptor (MET).
Athira Pharma overview
Athira Pharma, is a biopharmaceutical company that develops small molecules to treat neurodegenerative diseases and restore neuronal health. It is investigating ATH-1017, a small molecule drug for the treatment of Alzheimer’s and Parkinson’s disease; ATH-1020 against neuropsychiatric disorders; and Early Compounds that is Neuropathic Pain. The company works in partnership with contract development and manufacturing organizations to manufacture and supply preclinical and clinical materials for development of product candidates. Athira Pharma is headquartered in Bothell, Washington, the US.
For a complete picture of ATH-1020’s drug-specific PTSR and LoA scores, buy the report here.